Efficacy And Safety Of Daratumumab In A Frail Real-Life Relapsed Or Refractory Systemic Light-Chain Amyloidosis Population (Al): Report On 15 Cases From The North Of France

Introduction: Systemic Light-chain amyloidosis (AL) is a clonal plasma-cell disorder, and has therefore benefited from the numerous therapeutic advances in multiple myeloma (MM). Nonetheless, outcome of refractory AL patients remains dire, especially in patients with severe end-organ damage. Daratumumab, a monoclonal antibody directed against CD38, has yielded significant results in MM, but data in AL, although promising, are scarce.